ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Fernando
Escalante Barrigón
Publicaciones en las que colabora con Fernando Escalante Barrigón (11)
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival
British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2017
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
2016
-
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma
Leukemia, Vol. 30, Núm. 10, pp. 2026-2031
2015
-
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
Leukemia
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
-
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma
Blood, Vol. 124, Núm. 8, pp. 1300-1303
-
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification
Leukemia, Vol. 28, Núm. 1, pp. 166-173
2013
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728